AGP Picks
View all

Healthcare Times Utah
Provided by AGP

Healthcare Times Utah: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Times Utah.

August 2026

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31

September 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30

October 2026

Mo Tu We Th Fr Sa Su
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31

Press releases published on October 16, 2026

OXB Appoints Joachim Kreuzburg as Independent Non-Executive Director
Oct. 16, 2026

OXB Appoints Joachim Kreuzburg as Independent Non-Executive Director

Indeterminate GlobeNewswire
Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types
Oct. 16, 2026

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types

Indeterminate GlobeNewswire
Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026
Oct. 16, 2026

Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026

Indeterminate GlobeNewswire
Fractyl Health's Revita Meets Six-Month Co-Primary Endpoint in Ongoing REMAIN-1 Pivotal Study, With Highly Statistically Significant Reduction in Weight Regain After GLP-1 Discontinuation
Oct. 16, 2026

Fractyl Health's Revita Meets Six-Month Co-Primary Endpoint in Ongoing REMAIN-1 Pivotal Study, With Highly Statistically Significant Reduction in Weight Regain After GLP-1 Discontinuation

Indeterminate GlobeNewswire
Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis
Oct. 16, 2026

Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis

Indeterminate GlobeNewswire
Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer’s Disease
Oct. 16, 2026

Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer’s Disease

Indeterminate GlobeNewswire
Senturi Pharma announces exclusive European distribution agreement for PERTZYE®
Oct. 16, 2026

Senturi Pharma announces exclusive European distribution agreement for PERTZYE®

Indeterminate GlobeNewswire
Three Orelabrutinib Studies Presented in Oral Sessions at the 88th Annual Meeting of the Japanese Society of Hematology
Oct. 16, 2026

Three Orelabrutinib Studies Presented in Oral Sessions at the 88th Annual Meeting of the Japanese Society of Hematology

Indeterminate GlobeNewswire
Microbiotica Raises £36 Million ($48 Million) in Series C Financing to Advance Pipeline into Phase 2 Clinical Development
Oct. 16, 2026

Microbiotica Raises £36 Million ($48 Million) in Series C Financing to Advance Pipeline into Phase 2 Clinical Development

Indeterminate GlobeNewswire
Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Enrolls First Patient in Phase Ib/II Combination Trial in Metastatic Colorectal Cancer
Oct. 16, 2026

Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Enrolls First Patient in Phase Ib/II Combination Trial in Metastatic Colorectal Cancer

Indeterminate GlobeNewswire
City Therapeutics Announces Pricing of Upsized Initial Public Offering
Oct. 16, 2026

City Therapeutics Announces Pricing of Upsized Initial Public Offering

Indeterminate GlobeNewswire

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Healthcare Times Utah

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.